Objective:To evaluate the effect of cardiac function in breast cancer(BC)patients with BRCA1/2 mu-tation treated with anthracyclines.Methods:The subjects were 288 BC patients with normal blood pressure receiving long-term treatment of anthracycline.According to different genes,the patients were divided into BRCA1/2 gene mu-tation patients group (BRCA1/2 group,n＝138)and sporadic patients group (sporadic group,n＝150).Monitored and compared left ventricular ejection fraction (LVEF)and the overall longitudinal strain (GLS)of the two groups of patients by echocardiography.Results:The BRCA1/2 group had longer anthracycline treatment-to-enrollment time [(93.6 ± 15.6)months vs (49.2 ± 10.8)months,P＜0.001].There were no significant differences in heart func-tion and hemodynamic variables between two groups(all P＞0.05).Most of the patients had normal LVEF (92.4%) and GLS (83.3%).The differences of two groups with abnormal LVEF and GLS differences (P ＞0.05 ).Conclusion:The cardiac risk with the use of standard-doses of adjuvant anthracyclines in treatment of BRCA1/2 mutation carriers with BC.%目的:观察蒽环类药物治疗对BRCA1/2基因突变的乳腺癌(breast cancer,BC)患者心功能的影响.方法:研究对象为288例乳腺癌患者,长期接受蒽环类药物治疗,且血压正常.据基因不同,分为BRCA1/2基因突变患者组(BRCA1/2组,n＝138)和散发患者组(散发组,n＝150).通过超声心动图监测并比较二组患者的左室射血分数(LVEF)和整体纵向应变(GLS).结果:BRCA1/2基因突变患者蒽环类药物治疗时间显著长于散发组患者[(93.6 ± 15.6)个月 vs (49.2 ± 10.8)个月,P＜0.001].两组间血流动力学和超声心动图变量差异无统计学意义(均P＞0.05),绝大多数患者LVEF(92.4%)与GLS(83.3%)指标正常,两组患者LVEF与GLS异常患者比例差异无统计学意义(P＞0.05).结论:标准剂量的辅助蒽环类药物治疗对BRCA1/2基因突变BC患者心脏功能无显著影响.
展开▼
